StockData

ANI Pharmaceuticals vs Supernus

ANIP and SUPN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ANIP and SUPN compare

ANI Pharmaceuticals grew revenue faster over the last twelve months (30.9% versus 16.3% for Supernus).

Supernus keeps more of each dollar of sales as profit, with a net margin of 32.8% compared with 11.1% at ANI Pharmaceuticals.

ANI Pharmaceuticals scores higher on the StockData Score (14 against 6 for Supernus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricANIPSUPN
Size and price
Market cap$1.6B–
Share price$70.89$28.83
Change, 1 year−16.2%−3.4%
Change, 5 years73.9%–
Beta (5Y)0.631.32
Employees970838
StockData Score
Total score14 (better)6
Valuation score5 (better)0
Growth score23 (better)
Performance score4 (better)2
Health score3 (better)1
Dividend score00
Valuation
P/E15.1×–
P/S1.7×–
P/B2.7×–
EV/EBITDA6.6×–
P/FCF9.4×–
FCF yield10.6%–
Fair value$134.15–
Margin of safety47.2%–
Growth
Revenue growth (TTM)30.9% (better)16.3%
Revenue growth, 5Y average33.5%–
Net income growth (TTM)–252%
EPS growth (TTM)–253%
Profitability
Gross margin60.4%85.0% (better)
Operating margin15.4%40.6% (better)
Net margin11.1%32.8% (better)
FCF margin17.7% (better)2.3%
Return on equity21.0%–
Return on invested capital21.3%–
Financial health
Debt / equity0.50–
Net debt / EBITDA−0.250.32 (better)
Interest coverage4.8×32.8× (better)
Current ratio2.91 (better)0.61
Altman Z-score2.54–
Piotroski F-score7 (better)4
Dividends and buybacks
Payout ratio0.32%–
Buyback yield1.4%–
Shareholder yield1.4%–
Ownership
Held by institutions100%104%
Held by insiders12.3%16.4%
Insider net buying, 12 months−$13.6M−$2.5M (better)
Short interest, % of float17.8%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.